Abstract: A method and system for protecting sensitive data in a generative AI system is disclosed. The method includes encrypting sensitive data fields at a field level using a first encryption proxy in a data store, labeling the encrypted data fields with metadata in the data store, interfacing the data store to the generative AI system, receiving a user prompt at a second proxy, sending the user prompt to the generative AI system, generating a response by the generative AI system, receiving the response from the generative AI system, and selectively decrypting, by the second proxy, sensitive data in the response based on user authorization. In some embodiments, the metadata comprises encryption keys information and access control policies.

Abstract: The present embodiments relate to systems and methods to selectively encrypt data for a generative artificial intelligence (GenAI) application. The systems and methods as described herein provide access control for generative AI applications by applying encryption at the data level for all sensitive and regulated data values. Each data value identified as containing sensitive data can be individually encrypted with associated metadata that supports downstream processing by generative AI components and for access control. The encryption can be performed by inline network proxies that are configured by a centralized configuration management service. The use of centralized configuration management can be used for encryption and associated access control policies that is consistent across all of the data paths into and out of the protected systems.

Abstract: Disclosed is a system and method for the combustion of biomass material employing a swirling fluidized bed combustion (SFBC) chamber, and preferably a second stage combustion carried out in a cyclone separator. In the combustion chamber, primary air is introduced from a bottom air box that fluidizes the bed material and fuel, and staged secondary air is introduced in the tangential direction and at varied vertical positions in the combustion chamber so as to cause the materials in the combustion chamber (i.e., the mixture of air and particles) to swirl. The secondary air injection can have a significant effect on the air-fuel particle flow in the combustion chamber, and more particularly strengthens the swirling flow, promotes axial recirculation, increases particle mass fluxes in the combustion chamber, and retains more fuel particles in the combustion chamber. This process increases the residence time of the particle flow.

Abstract: Methods to secure against IP address thefts by rogue devices in a virtualized datacenter are provided. Rogue devices are detected and distinguished from a migration of an endpoint in a virtualized datacenter. A first hop network element in a one or more network fabrics intercepts a request that includes an identity of an endpoint and performs a local lookup for the endpoint entity identifier. Based on the lookup not finding the endpoint entity identifier, the first hop network element broadcasts a message such as a remote media access address (MAC) query to other network elements in the one or more network fabrics. Based on the received response, which may include an IP address associated with the MAC address, the first hop network element performs a theft validation process to determine whether the request originated from a migrated endpoint or a rogue device.

Abstract: Methods to secure against IP address thefts by rogue devices in a virtualized datacenter are provided. Rogue devices are detected and distinguished from a migration of an endpoint in a virtualized datacenter. A first hop network element in a one or more network fabrics intercepts a request that includes an identity of an endpoint and performs a local lookup for the endpoint entity identifier. Based on the lookup not finding the endpoint entity identifier, the first hop network element broadcasts a message such as a remote media access address (MAC) query to other network elements in the one or more network fabrics. Based on the received response, which may include an IP address associated with the MAC address, the first hop network element performs a theft validation process to determine whether the request originated from a migrated endpoint or a rogue device.

Abstract: Methods to secure against IP address thefts by rogue devices in a virtualized datacenter are provided. Rogue devices are detected and distinguished from a migration of an endpoint in a virtualized datacenter. A first hop network element in a one or more network fabrics intercepts a request that includes an identity of an endpoint and performs a local lookup for the endpoint entity identifier. Based on the lookup not finding the endpoint entity identifier, the first hop network element broadcasts a message such as a remote media access address (MAC) query to other network elements in the one or more network fabrics. Based on the received response, which may include an IP address associated with the MAC address, the first hop network element performs a theft validation process to determine whether the request originated from a migrated endpoint or a rogue device.

Abstract: Disclosed is a system and method for the combustion of biomass material employing a swirling fluidized bed combustion (SFBC) chamber, and preferably a second stage combustion carried out in a cyclone separator. In the combustion chamber, primary air is introduced from a bottom air box that fluidizes the bed material and fuel, and staged secondary air is introduced in the tangential direction and at varied vertical positions in the combustion chamber so as to cause the materials in the combustion chamber (i.e., the mixture of air and particles) to swirl. The secondary air injection can have a significant effect on the air-fuel particle flow in the combustion chamber, and more particularly strengthens the swirling flow, promotes axial recirculation, increases particle mass fluxes in the combustion chamber, and retains more fuel particles in the combustion chamber. This process increases the residence time of the particle flow.

Abstract: The present invention relates to formulations of concentrated azalide antibiotics and methods for making and using them. Specifically, the invention relates to a method of treating an infection comprising administering to a patient in need thereof, an effective amount of a concentrated aqueous azalide antibiotic formulation made according to the method comprising dissolving an azalide antibiotic in an aqueous solution comprising a strong acid. The invention also relates to methods for making concentrated aqueous azalide antibiotic formulations for use in pulmonary infection, a nasopharyngeal infection, an otic infection, an ocular infection, a dermal or a vaginal infection. The invention also relates to concentrated aqueous azalide antibiotic formulations made by dissolving an azalide antibiotic in an aqueous solution comprising a strong acid.

Abstract: The present invention relates to formulations of concentrated azalide antibiotics and methods for making and using them. Specifically, the invention relates to a method of treating an infection comprising administering to a patient in need thereof, an effective amount of a concentrated aqueous azalide antibiotic formulation made according to the method comprising dissolving an azalide antibiotic in an aqueous solution comprising a strong acid. The invention also relates to methods for making concentrated aqueous azalide antibiotic formulations for use in pulmonary infection, a nasopharyngeal infection, an otic infection, an ocular infection, a dermal or a vaginal infection. The invention also relates to concentrated aqueous azalide antibiotic formulations made by dissolving an azalide antibiotic in an aqueous solution comprising a strong acid.

Abstract: The present invention relates to formulations of concentrated azalide antibiotics and methods for making and using them. Specifically, the invention relates to a method of treating an infection comprising administering to a patient in need thereof, an effective amount of a concentrated aqueous azalide antibiotic formulation made according to the method comprising dissolving an azalide antibiotic in an aqueous solution comprising a strong acid. The invention also relates to methods for making concentrated aqueous azalide antibiotic formulations for use in pulmonary infection, a nasopharyngeal infection, an otic infection, an ocular infection, a dermal or a vaginal infection. The invention also relates to concentrated aqueous azalide antibiotic formulations made by dissolving an azalide antibiotic in an aqueous solution comprising a strong acid.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: A membrane capable of inhibiting agent release from a delivery system when no electrical current is flowing and yet provide minimal impedance to electrically-assisted agent delivery, useful both for incorporating into electrotransport agent delivery systems and for use in measuring agent release rates in in vitro testing.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: A controlled release medicament delivery system comprises a plasticized bioerodible polymer, such as a polyorthoester. Medicament desirably is entrapped in the plasticized polymer. The resulting delivery system is able to release the medicament in a controlled and sustained manner. The formulation is particularly advantageous for use as a once-a-day eyedrop. During preparation, the polymer may be heated to an elevated temperature for a sufficient time to substantially reduce its molecular weight.

Abstract: A process for the treatment of a soft contact lens, to increase its resistance to the deposition thereon and diffusion and accumulation therein of substances which will promote its clouding and discoloration in use, and to improve its mechanical strength, includes treating a hydroxyl group-containing acrylic ester soft contact lens or replica with an organic acid anhydride for a sufficient period of time to treat at least a portion of polymer molecules on the outer surfaces, e.g. by esterifying hydroxyl groups on the molecules and facilitating extraction of organic-type impurities. The process is optionally performed in the presence of a medium which partially swells the surface regions of the lens or replica prior to or during the process.

Abstract: A contact lens for correction of astigmatism is formed from a single polymeric or copolymeric material. The lens has a central optical zone of greater rigidity than a surrounding non-optical zone. The rigidity of the central optical zone is sufficient for it to retain an astigmatism-correcting shape when worn on an eye, while the surrounding non-optical zone conforms to the shape of the eye.

Abstract: Method and therapeutic system in the form of a bandage that administer scopolamine base transdermally in an initial pulse of 10 to 200 .mu.g/cm.sup.2 of skin that quickly brings the concentration of scopolamine in the plasma to a level at which emesis and nausea are inhibited without intolerable side effects, followed by a substantially constant dosage in the range of 0.3 to 15 .mu.g/hr that holds said level. The bandage is a four-layer laminate of, from the top: a protective backing; a gelled, mineral oil-polyisobutene-scopolamine reservoir lamina that is the source of the constant dosage; a microporous membrane that controls the constant dosage rate; and a gelled, mineral oil-polyisobutene-scopolamine adhesive layer that is the source of the pulse dose and the means by which the bandage is attached to the skin.